Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 24, 2017 16:00 ET | Source: Radius Health Inc.

Radius Announces Positive Top-Line Results from Completed ACTIVExtend Study for TYMLOS™ in Postmenopausal Women with Osteoporosis

ACTIVExtend trial demonstrated sustained statistically significant fracture risk reduction through the 3.5 years of sequential therapy: TYMLOS followed by an antiresorptive Safety similar...
May 15, 2017 16:15 ET | Source: Radius Health Inc.

Radius Health Announces New Employment Inducement Grant

WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to...
May 15, 2017 07:00 ET | Source: Radius Health Inc.

Radius Health Appoints Pharmaceutical Executive Jose Carmona as Chief Financial Officer

WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to...
May 01, 2017 06:30 ET | Source: Radius Health Inc.

Radius Health Reports First Quarter 2017 Financial and Operating Results

US FDA approves TYMLOS™ (abaloparatide) on April 28, 2017, first new bone builder in nearly 15 years US Launch set for May 2017 24-month ACTIVExtend trial has concluded, Radius to report top-line...
April 28, 2017 10:43 ET | Source: Radius Health Inc.

FDA Approves Radius Health’s TYMLOS™ (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture

TYMLOS is the first new anabolic (bone building) agent for postmenopausal women with osteoporosis in the United States in nearly 15 years US Commercial Launch in May Approval Based on Results at 18...
April 05, 2017 16:13 ET | Source: Radius Health Inc.

Radius Health Announces Presentations at Upcoming Conferences and Its Plans to Announce First Quarter Financial Results on May 3, 2017

WALTHAM, Mass., April 05, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing innovative therapeutics in the areas of...
April 03, 2017 07:00 ET | Source: Radius Health Inc.

New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies

The data was presented in an Oral Late-Breaker at Annual Endocrine Society Meeting “ENDO 2017” on April 1 Additional analysis of BMD gains at the wrist and fracture reductions at the ultradistal...
March 31, 2017 11:30 ET | Source: Radius Health Inc.

Radius Health Announces Three Presentations on Elacestrant (RAD1901) and RAD140 at the 2017 American Association for Cancer Research Annual Meeting (AACR)

Preclinical models of elacestrant activity in preclinical models of endocrine treatment resistancePreclinical studies of RAD140 activity and mechanism of action in breast cancer models WALTHAM,...
March 10, 2017 09:17 ET | Source: Radius Health Inc.

Radius Health Receives Notification of PDUFA Extension for Abaloparatide-SC

WALTHAM, Mass., March 10, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS), a science-driven biopharmaceutical company that is committed to developing...
February 28, 2017 07:00 ET | Source: Radius Health Inc.

Radius Health to Present at Cowen and Company 37th Annual Health Care Conference

WALTHAM, Mass., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing innovative therapeutics in the areas of...